Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Because nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its antitumor immune response is of great interest to dermato-oncologists. In this report, we describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy, using contact sensitizing agents, such as squaric acid dibutylester and diphencyprone. In addition, immunohistochemical staining supported one of the possible mechanisms of this combination therapy. Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy.

Original languageEnglish
Pages (from-to)686-689
Number of pages4
JournalJournal of Dermatology
Volume43
Issue number6
DOIs
Publication statusPublished - 2016 Jun 1

Keywords

  • Contact immunotherapy
  • Immunohistochemical staining
  • Melanoma
  • Nivolumab
  • PD-1/PD-L1 blockade

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports'. Together they form a unique fingerprint.

Cite this